Logo image of BVXV

BIONDVAX PHARMACEUTICALS-ADR (BVXV) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BVXV - US09073Q2049 - ADR

1.36 USD
+0.05 (+3.82%)
Last: 9/6/2023, 8:00:01 PM
1.38 USD
+0.02 (+1.47%)
After Hours: 9/6/2023, 8:00:01 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BVXV. BVXV was compared to 190 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of BVXV have multiple concerns. BVXV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BVXV has reported negative net income.
BVXV Yearly Net Income VS EBIT VS OCF VS FCFBVXV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for BVXV are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BVXV Yearly ROA, ROE, ROICBVXV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 100 -100 200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BVXV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BVXV Yearly Profit, Operating, Gross MarginsBVXV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for BVXV has been increased compared to 1 year ago.
The debt/assets ratio for BVXV is higher compared to a year ago.
BVXV Yearly Shares OutstandingBVXV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M
BVXV Yearly Total Debt VS Total AssetsBVXV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

BVXV has an Altman-Z score of -7.98. This is a bad value and indicates that BVXV is not financially healthy and even has some risk of bankruptcy.
BVXV has a worse Altman-Z score (-7.98) than 72.12% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.98
ROIC/WACCN/A
WACCN/A
BVXV Yearly LT Debt VS Equity VS FCFBVXV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

BVXV has a Current Ratio of 4.28. This indicates that BVXV is financially healthy and has no problem in meeting its short term obligations.
BVXV has a Current ratio (4.28) which is in line with its industry peers.
A Quick Ratio of 4.28 indicates that BVXV has no problem at all paying its short term obligations.
BVXV has a Quick ratio (4.28) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.28
Quick Ratio 4.28
BVXV Yearly Current Assets VS Current LiabilitesBVXV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

BVXV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -93.48%.
EPS 1Y (TTM)-93.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BVXV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.98% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.29%
EPS Next 2Y18.02%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BVXV Yearly EPS VS EstimatesBVXV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BVXV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BVXV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BVXV Price Earnings VS Forward Price EarningsBVXV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BVXV Per share dataBVXV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as BVXV's earnings are expected to grow with 24.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.02%
EPS Next 3Y24.98%

More info and screens

0

5. Dividend

5.1 Amount

BVXV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONDVAX PHARMACEUTICALS-ADR

NASDAQ:BVXV (9/6/2023, 8:00:01 PM)

After market: 1.38 +0.02 (+1.47%)

1.36

+0.05 (+3.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11 2023-08-11/bmo
Earnings (Next)N/A N/A
Inst Owners6.93%
Inst Owner Change0%
Ins Owners18.86%
Ins Owner Change0%
Market Cap4.97M
Revenue(TTM)N/A
Net Income(TTM)-10.92M
Analysts82.86
Price Target39.78 (2825%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.39%
Min EPS beat(2)-46.39%
Max EPS beat(2)-46.39%
EPS beat(4)2
Avg EPS beat(4)48.25%
Min EPS beat(4)-46.39%
Max EPS beat(4)109.8%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.86
EYN/A
EPS(NY)-2.6
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-1.32
TBVpS-1.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.28
Quick Ratio 4.28
Altman-Z -7.98
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)239.78%
Cap/Depr(5y)2174.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.5%
EPS Next Y99.29%
EPS Next 2Y18.02%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-229.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y91.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y91.08%
OCF growth 3YN/A
OCF growth 5YN/A

BIONDVAX PHARMACEUTICALS-ADR / BVXV FAQ

What is the ChartMill fundamental rating of BIONDVAX PHARMACEUTICALS-ADR (BVXV) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BVXV.


What is the valuation status of BIONDVAX PHARMACEUTICALS-ADR (BVXV) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIONDVAX PHARMACEUTICALS-ADR (BVXV). This can be considered as Overvalued.


Can you provide the profitability details for BIONDVAX PHARMACEUTICALS-ADR?

BIONDVAX PHARMACEUTICALS-ADR (BVXV) has a profitability rating of 0 / 10.


What is the earnings growth outlook for BIONDVAX PHARMACEUTICALS-ADR?

The Earnings per Share (EPS) of BIONDVAX PHARMACEUTICALS-ADR (BVXV) is expected to grow by 99.29% in the next year.